JP7255157B2 - external composition - Google Patents

Description

TECHNICAL FIELD The present invention relates to an external composition containing a placenta extract and having excellent production suitability and formulation stability.

Placenta extract is an extract extracted from the placenta of animals, etc., and is known for its skin turnover, enhancement of skin barrier function, antioxidant effect, etc., so it is widely used in oral and external preparations, and is widely used in the medical field. and in the beauty field. While it is shown to be useful for the skin in this way, it is known that it is difficult to stably incorporate it into formulations because it is poorly compatible with other ingredients and causes discoloration and odor over time. It is reported that it can be solved by blending with a large amount of phospholipid (Patent Document 1).

JP-A-2005-336127

The present inventors produced a composition for external use containing a placenta extract, and found that the formulation foamed during preparation. Furthermore, when the produced placenta extract-containing formulation was stored, sediment occurred over time, and it was found that there was a problem with formulation stability. To date, there have been no reports of formulation stability problems such as foaming during production and sedimentation over time in the produced formulation when a placenta extract is blended into the formulation. Foaming at the time of production is not preferable from the viewpoint of impairing the uniformity of the formulation and also causing variation in filling amount. In addition, the generation of sediment is accompanied by a change in appearance, which significantly impairs the commercial value. Therefore, in order to provide placenta-blended preparations, it is required to improve the stability of the preparation and to suppress foaming during production.

An object of the present invention is to provide a composition for external use containing a placenta extract and having excellent production suitability and formulation stability.

As a result of intensive studies to solve the above problems, the present inventors have found that an external composition containing a placenta extract and water contains a heparin-like substance and at least one selected from Coptis extract, Phellodendron bark extract, and seaweed extract. The inventors have found that the above problems can be solved by blending the above, and have completed the present invention.

That is, the present invention
(1) characterized by containing (a) placenta extract, (b) heparin-like substances, and (c) at least one selected from the group consisting of Coptis extract, Phellodendron bark extract, and seaweed extract, and (d) water A composition for external use,
(2) The composition for external use according to (1), wherein the dosage form is a lotion, cream, milky lotion, gel, or pack;
(3) The composition for external use according to (1) or (2), wherein the composition for external use is a cosmetic, a quasi-drug, or a drug;
is.

INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide an external composition containing a placenta extract and having excellent production suitability and formulation stability.

For each component used in the composition for external use of the present invention, those having the quality normally used in pharmaceuticals, quasi-drugs, or cosmetics can be appropriately used.

The origin of the placenta extract in the composition for external use of the present invention includes, for example, human, bovine, porcine, horse, and sheep, preferably porcine. In addition, commercially available placenta extracts (eg, biocatalyst placenta APF (SW) (M-PE-APF)) may be used.
The content of the placenta extract in the topical composition of the present invention is preferably 0.01 to 5 w/w%, more preferably 0.1 to 0.5 w/w%.

The content of the heparin analogue in the composition for external use of the present invention is preferably 0.01 to 5 w/w%, more preferably 0.1 to 0.5 w/w%. Also, it is preferably 0.001 to 500 parts by mass, more preferably 0.01 to 50 parts by mass, based on 1 part by mass of the placenta extract.

The coptis extract in the present invention is Coptis japonica (scientific name: Coptis japonica Makino) belonging to the family Ranunculaceae and the genus Coptis. Above-ground parts such as parts, seed parts, and flower parts, rhizome parts, or mixtures of these parts, etc., may be mentioned, but rhizome parts are preferred. A method for extracting the above extract is not particularly limited, and can be carried out according to a conventional method. Either a polar solvent or a non-polar solvent can be used as the extraction solvent used for extraction. For example, water, ethanol, propylene glycol, 1,3-butylene glycol, and mixtures thereof can be used. The above extract may be used as an extracted solution, or if necessary, may be used after being subjected to concentration, dilution, filtration, decolorization with activated charcoal or the like, deodorization, ethanol precipitation, or the like. Furthermore, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product. Moreover, a commercial item can also be used.

Phellodendron amurense Ruprecht, a deciduous tall tree belonging to the genus Amurensis of the Rutaceae family, is used as the Phellodendron bark extract in the present invention. Fruit kernels, mixtures of these parts, etc. can be mentioned, but bark parts are preferred. A method for extracting the above extract is not particularly limited, and can be carried out according to a conventional method. Either a polar solvent or a non-polar solvent can be used as the extraction solvent used for extraction. For example, water, ethanol, propylene glycol, 1,3-butylene glycol, and mixtures thereof can be used. The above extract may be used as an extracted solution, or if necessary, may be used after being subjected to concentration, dilution, filtration, decolorization with activated charcoal or the like, deodorization, ethanol precipitation, or the like. Furthermore, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product. Moreover, a commercial item can also be used.

The seaweed extract in the present invention is an extract obtained by extracting from brown algae (Phaeophyta), red algae (Rhodophyta), green algae (Chlorophyta) and the like. Examples of brown algae include fucus and kelp. Examples of red algae include Aegis. Examples of green algae include Aonori. Among these seaweeds, brown algae are preferable, and fucus is particularly preferable. Examples of commercially available seaweed extracts include seaweed extract BG-J (fucus extract, manufactured by Maruzen Pharmaceutical Co., Ltd.), Falcolex fucus (fucus extract, manufactured by Ichimaru Falcos Co., Ltd.), and the like. Among these, the sea bream extract BG-J is preferred. The method for extracting the seaweed extract is not particularly limited, and can be carried out according to a conventional method. Either a polar solvent or a non-polar solvent can be used as the extraction solvent used for extraction. For example, water, ethanol, propylene glycol, 1,3-butylene glycol, and mixtures thereof can be used. The above extract may be used as an extracted solution, or if necessary, may be used after being subjected to concentration, dilution, filtration, decolorization with activated charcoal or the like, deodorization, ethanol precipitation, or the like. Furthermore, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product. Moreover, a commercial item can also be used.

The content of the Coptis chinensis extract, Phellodendron bark extract, and seaweed extract in the composition for external use of the present invention is preferably 0.0001 to 10 w/w%, more preferably 0.01 to 1 w/w%. Also, it is preferably 0.001 to 1000 parts by mass, more preferably 0.01 to 500 parts by mass, based on 1 part by mass of the heparinoid.

The composition for external use of the present invention contains water. The content of water in the topical composition of the present invention is preferably 1 to 99.9 w/w%, more preferably 50 to 99.9 w/w%.

In addition to the above components, the composition for external use of the present invention can appropriately contain various components used in ordinary cosmetics, quasi-drugs, pharmaceuticals, etc., as long as the effects of the present invention are not impaired. For example, pH adjusters (citric acid, sodium citrate, potassium hydroxide, sodium hydroxide, etc.), fragrances, cooling agents (menthol, peppermint oil, camphor, etc.), anti-inflammatory agents (salicylic acid, glycyrrhizic acid or its salts, glycyrrhetinic acid, allantoin, etc.), fungicides (chlorhexidine gluconate, isopropylmethylphenol, etc.), preservatives (parabens (methylparaben, butylparaben, propylparaben, etc.), benzoic acid or its salts, phenoxyethanol, etc.), moisturizing agents (hyaluron) acid or its salt, chondroitin sulfate, polyhydric alcohol (glycerin, diglycerin, 1,3-butylene glycol, propylene glycol, 1,2-pentanediol, etc.), amino acid (L-serine, L-proline, L-hydroxyproline etc.), extracts of various animals and plants (Peonies, licorice, rosemary, sage, etc.), vitamins (retinol palmitate, ascorbic acid, thiamine nitrate, cyanocobalamin, biotin, riboflavin, nicotinamide, etc.), antioxidants (dibutylhydroxytoluene, sodium pyrosulfite, tocopherol, sodium edetate, ascorbic acid, isopropyl gallate, etc.), solubilizers (vegetable oils, animal oils, alkylglyceryl ethers, hydrocarbons, etc.), metabolic activators, gelling agents (Water-soluble polymers (carboxyvinyl polymer, hydroxyethylcellulose, hydroxypropylmethylcellulose, etc.), oily gelling agents (inulin stearate, dextrin palmitate, etc.), adhesives, and the like. The amount of these components to be added is not particularly limited, and can be appropriately determined in consideration of the feeling of use and the like.

The composition for external use of the present invention can be used for applications such as cosmetics, quasi-drugs, and pharmaceuticals.

The composition for external use in the present invention is a composition for external use containing water as component (d).

The form of the composition for external use of the present invention is not particularly limited as long as it is a dosage form that can be applied to the skin. Specific dosage forms include lotions, creams, milky lotions, gels, packs, bath salts and the like. Among these dosage forms, lotions and creams are particularly preferred. The composition for external use of the present invention can be produced by a conventional method depending on the dosage form.

EXAMPLES The present invention will be described in detail below with reference to Examples, Comparative Examples and Test Examples, but the present invention is not limited to the following examples. In addition, in the examples and comparative examples, all the numerical values mean % by mass.

(Method for preparing composition for external use)
According to the formulations shown in Tables 1 to 4 below, placenta extract (Biocatalyst Placenta APF (SW) (M-PE-APF) manufactured by BIODELL BIOCHEMICAL SA), heparin analogues, various extracts (Oobac extract: Maruzen Pharmaceutical Co., Ltd.) Phellodendron bark extract BG-J manufactured by Co., Ltd. Coptis extract: Falcorex Coptis B manufactured by Ichimaru Falcos Co., Ltd. Seaweed extract: Kaisou extract BG-J manufactured by Maruzen Pharmaceutical Co., Ltd.) are uniformly dissolved in purified water, External compositions of Examples 1-5 and Comparative Examples 1-7 were obtained.

(Test Example 1: Foaming Evaluation 1)
A 20 mL centrifuge tube was filled with 5 mL of the compositions for external use of Examples 1 and 2 and Comparative Example 1, and shaken at 315 rpm for 5 minutes with a shaker. The state of the foam immediately after was visually confirmed and evaluated.

The composition for external use of Comparative Example 1 containing placenta extract and heparin-like substance produced large bubbles, but the addition of Phellodendron bark extract or seaweed extract produced only a few fine bubbles and suppressed foaming. I was able to

(Test Example 2: Foaming Evaluation 2)
100 mL of the external use compositions of Examples 3 to 5 and Comparative Examples 2 and 3 were placed in a 200 mL glass beaker and stirred at 1500 rpm for 10 minutes using a homomixer. The height of foam generated after stirring was measured.

Foaming occurred in a topical composition containing placenta extract alone or a placenta extract and a heparinoid, but the foaming was suppressed by adding Coptis extract or Phellodendron bark extract.

(Test Example 3: Evaluation of sediment)
A glass container was filled with 100 mL of each external composition of Examples 3 and 4 and Comparative Examples 4 to 7 and stored at room temperature for 1 week. The occurrence of sediment after storage was visually evaluated.
(Evaluation criteria for sediment)
○: No sediment ×: Sediment present

(Test Example 4: Evaluation of sediment)
A glass container was filled with 100 mL of each external composition of Example 5 and Comparative Example 3 and stored at room temperature for 2 weeks. The occurrence of sediment after storage was visually evaluated.
(Evaluation criteria for sediment)
○: No sediment ×: Sediment present

Sedimentation occurred in the topical compositions containing placenta extract alone or placenta extract and coptis extract, Phellodendron bark extract, or seaweed extract.

As described above, by blending a heparin-like substance with one or more extracts selected from Coptis extract, Phellodendron bark extract, and seaweed extract, foaming and sedimentation of the external composition containing placenta extract could be suppressed at the same time.

(prescription example)
According to the formulation shown in Table 5 below, each component was uniformly dissolved in water to obtain a composition for external use. In addition, all the numerical values of the prescription examples 1 and 2 shall mean the mass % below.

*1: The 2-methacryloyloxyethylphosphorylcholine/stearyl methacrylate copolymer-containing composition used was trade name “Lipidure-NR” (manufactured by NOF Corporation).
*2: Ascorbyl tetra-2-hexyldecanoate-containing composition used the product name “SBG-24” (manufactured by Yamakawa Trading Co., Ltd.).

INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide an external composition containing a placenta extract and having excellent production suitability and formulation stability.

Claims (3)

A composition for external use comprising (a) a placenta extract, (b) a heparinoid, (c) at least one selected from the group consisting of coptis extract, Phellodendron bark extract, and seaweed extract, and (d) water. thing. 2. The composition for external use according to claim 1, wherein the dosage form is a lotion, cream, emulsion, gel, or pack. 3. The composition for external use according to claim 1, wherein the composition for external use is a cosmetic, a quasi-drug, or a pharmaceutical.